Significance of concurrent use of weekly cisplatin in carbon-ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix: A propensity score-matched analysis.,Cancer Medicine

当前位置： X-MOL 学术 › Cancer Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Significance of concurrent use of weekly cisplatin in carbon-ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix: A propensity score-matched analysis.
Cancer Medicine ( IF 2.9 ) Pub Date : 2019-12-31 , DOI: 10.1002/cam4.2784
Noriyuki Okonogi ₁ , Masaru Wakatsuki ₂ , Shingo Kato ₃ , Hiroto Murata _{1,

4} , Hiroki Kiyohara ₅ , Kumiko Karasawa ₆ , Tatsuya Ohno ₄ , Hiroshi Tsuji ₁ , Takashi Nakano ₁ , Makio Shozu ₇ ,

Affiliation

BACKGROUND Although carbon-ion radiotherapy (C-ion RT) with concurrent chemotherapy (chemo-C-ion RT) is a promising treatment for adenocarcinoma (AC) of the uterine cervix, its long-term efficacy remains unclear. We evaluated the long-term significance of concurrent weekly cisplatin and C-ion RT for locally advanced AC of the uterine cervix. METHODS We performed a pooled analysis of patients with stage IIB-IVA AC of the uterine cervix who underwent C-ion RT alone or chemo-C-ion RT between September 2007 and December 2018 at our institution. Patients received 74.4 Gy (relative biological effectiveness) with or without cisplatin (40 mg/m2 per week for up to 5 weeks), underwent no prior pelvic RT or systemic therapy, and had a performance status of 0-2. Propensity score matching was based on the year of diagnosis, regional lymph node metastasis, and stage. RESULTS The matched cohort contained 26 patients who underwent C-ion RT and 26 who underwent chemo-C-ion RT. The median age and follow-up period were 57 (range, 28-79) years and 34 (range, 2-126) months, respectively. The 5-year overall survival rate was significantly better in the chemo-C-ion RT group (72%) than in the C-ion RT group (46%; P = .041). The 5-year distant metastatic-free rate was also significantly better in the chemo-C-ion RT group (66%) than in the C-ion RT group (41%; P = .048). The incidence of grade ≥ 3 late toxicities was comparable between the two groups. CONCLUSIONS Chemo-C-ion RT for locally advanced AC of the uterine cervix is associated with a long-term survival benefit.

中文翻译：

同时使用每周顺铂在局部局部晚期宫颈癌的碳离子放射治疗中的意义：倾向评分匹配分析。

背景技术尽管碳离子放射疗法（C-ion RT）与同步化疗（chemo-C-ion RT）是子宫宫颈腺癌（AC）的有前途的治疗方法，但其长期疗效尚不清楚。我们评估了每周一次顺铂和C离子RT联合治疗对子宫颈局部晚期AC的长期意义。方法我们对我院2007年9月至2018年12月间仅接受C离子RT或化学C离子RT的宫颈IIB-IVA AC期患者进行了汇总分析。患者接受或不联合使用顺铂（每周40 mg / m2，长达5周）的74.4 Gy（相对生物学有效性），以前未进行骨盆放疗或全身治疗，其工作状态为0-2。倾向得分匹配基于诊断年份，区域淋巴结转移，和舞台。结果匹配的队列包括26例接受C-离子RT治疗的患者和26例接受化学-C-离子RT治疗的患者。中位年龄和随访期分别为57（28-79）个月和34（2-126）个月。化学-C-离子RT组的5年总生存率（72％）明显优于C-离子RT组（46％； P = .041）。化学-C-离子RT组的5年远处无转移率也显着优于C-离子RT组（41％； P = .048）。两组中晚期毒性≥3级的发生率在两组之间相当。结论化学-C-离子RT治疗子宫颈局部晚期AC与长期生存获益有关。中位年龄和随访期分别为57（28-79）个月和34（2-126）个月。化学-C-离子RT组的5年总生存率（72％）明显优于C-离子RT组（46％； P = .041）。化学-C-离子RT组的5年远处无转移率也显着优于C-离子RT组（41％； P = .048）。两组之间≥3级晚期毒性的发生率相当。结论化学-C-离子RT治疗子宫颈局部晚期AC与长期生存获益有关。中位年龄和随访期分别为57（28-79）个月和34（2-126）个月。化学-C-离子RT组的5年总生存率（72％）明显优于C-离子RT组（46％； P = .041）。化学C离子RT组的5年远处无转移率也明显优于C离子RT组（41％； P = .048）。两组之间≥3级晚期毒性的发生率相当。结论化学-C-离子RT治疗子宫颈局部晚期AC与长期生存获益有关。化学-C-离子RT组的5年远处无转移率也显着优于C-离子RT组（41％； P = .048）。两组之间≥3级晚期毒性的发生率相当。结论化学-C-离子RT治疗子宫颈局部晚期AC与长期生存获益有关。化学-C-离子RT组的5年远处无转移率也显着优于C-离子RT组（41％； P = .048）。两组之间≥3级晚期毒性的发生率相当。结论化学-C-离子RT治疗子宫颈局部晚期AC与长期生存获益有关。

更新日期：2019-12-31

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11